Sanger Sequencing Global Market Report 2024

The sanger sequencing market size has grown rapidly in recent years. It will grow from $2.29 billion in 2023 to $2.75 billion in 2024 at a compound annual growth rate (CAGR) of 19.9%. The growth observed during the historical period can be attributed to several factors, including heightened demand for research, expanding applications in medical diagnostics, growing pharmaceutical development activities, increased utilization in agriculture, rising demand for forensic analysis, enhanced discovery of biomarkers, and growing studies in genetic evolution.

The sanger sequencing market size is expected to see rapid growth in the next few years. It will grow to $5.3 billion in 2028 at a compound annual growth rate (CAGR) of 17.8%. The growth anticipated in the forecast period is driven by several factors, including the increasing integration of clinical genomics, expanded applications in agricultural genomics, heightened focus on drug safety and pharmacogenomics, rising utilization of prenatal and newborn screening, and increased adoption of environmental DNA analysis. Major trends expected during this period include technological advancements, a growing demand for next-generation sequencing technologies, expanding applications in clinical diagnostics, increased investments in genomics research, and the widening use of genomics in personalized medicine.

The projected increase in genetic illnesses is set to drive the expansion of the Sanger sequencing market in the foreseeable future. Genetic illnesses, or genetic disorders, stem from abnormalities or mutations in an individual's DNA, the genetic material responsible for carrying hereditary information. Sanger sequencing plays a crucial role in diagnosing genetic illnesses by precisely determining the sequence of nucleotides (the DNA building blocks) within a specific gene or DNA region. For instance, data from the Genetic Rare Diseases Information Center (GARD), a US-based government agency, revealed approximately 7,000 known rare genetic diseases by February 2024, affecting approximately 1 in 10 individuals or around 30 million people in the United States during 2020-2021. Consequently, the surge in genetic illnesses acts as a catalyst propelling the growth of the Sanger sequencing market.

Major players within the Sanger sequencing market are investing in the development of advanced systems to drive revenue growth. These advanced systems are engineered to accommodate higher throughput, enabling the simultaneous processing of multiple samples. For example, in October 2021, Promega Corporation, a US-based manufacturer specializing in enzymes and related products, introduced the ProDye Terminator Sequencing System. This system is compatible with all capillary electrophoresis (CE) platforms, including the compact benchtop Spectrum Compact CE System. It enables research laboratories to conduct Sanger sequencing on any CE instrument, catering to a range of laboratory sizes. Leveraging a proprietary thermostable DNA polymerase, the ProDye Terminator Sequencing System can be deployed on various instruments such as the Spectrum Compact CE System, SeqStudio Genetic Analyzers, and Applied Biosystems Genetic Analyzers.

In January 2023, Qiagen, a German company specializing in sample and assay technologies, acquired Verogen for $150 million. This strategic move enables Qiagen to optimize its renowned sample extraction and library preparation automation capabilities, thereby bolstering the channel reach and market presence of both companies in support of the forensic market. Verogen, based in the United States, is a leading provider of Sanger sequencing solutions tailored for human identification and forensic laboratories.

Major companies operating in the sanger sequencing market report are Hoffmann-La Roche, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific, Illumina Inc., Beckman Coulter, PerkinElmer Inc., BGI Group, LGC Limited, GenScript, Oxford Nanopore Technologies, Pacific Biosciences of California Inc., Macrogen Inc., GENEWIZ Inc., Quintara Biosciences, CeMIA SA, Source BioScience, Microsynth AG, Fasteris SA, GenHunter Corporation, Nucleics Pty. Ltd., SciGenom Labs Pvt. Ltd., StarSEQ GmbH, GATC Biotech AG, Agilent Technologies.

North America was the largest region in the sanger sequencing market in 2023. The regions covered in the sanger sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sanger sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sanger sequencing, also known as chain termination sequencing, is a technique utilized to determine the nucleotide sequence of DNA. It finds application in smaller-scale projects and validating the results of deep sequencing, producing DNA sequence reads exceeding 500 nucleotides while maintaining high accuracy levels.

Sanger sequencing encompasses several types, including shotgun sequencing, targeted gene sequencing, and others. In shotgun sequencing, random fragments of a lengthy DNA molecule are sequenced in parallel and then pieced together using their overlapping segments. Laboratories employing Sanger sequencing methods can be categorized as wet labs or dry labs, while research endeavors can be conducted in-house or outsourced. These techniques are employed across various applications such as diagnostics, biomarkers, cancer research, reproductive health, personalized medicine, forensics, among others. Moreover, Sanger sequencing serves a diverse range of end-users including academic institutions, government research institutes, pharmaceutical companies, biotechnology firms, hospitals, and clinics.

The sanger sequencing market research report is one of a series of new reports that provides sanger sequencing market statistics, including sanger sequencing industry global market size, regional shares, competitors with a sanger sequencing market share, detailed sanger sequencing market segments, market trends, and opportunities, and any further data you may need to thrive in the sanger sequencing industry. This sanger sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sanger sequencing market includes revenues earned by entities by providing DNA synthesis, and targeted synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.